The Enterprise Value as of March 2026 (TTM) for Mineralys Therapeutics, Inc. (MLYS) is 1.56B

According to Mineralys Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.56B. This represents a change of -6.28% compared to the average of 1.67B of the last 4 quarters.

Mineralys Therapeutics, Inc. (MLYS) Historical Enterprise Value (quarterly & annually)

How has MLYS Enterprise Value performed in the past?

The mean historical Enterprise Value of Mineralys Therapeutics, Inc. over the last ten years is 534.17M. The current 1.56B Enterprise Value has changed 29.17% with respect to the historical average. Over the past ten years (40 quarters), MLYS's Enterprise Value was at its highest in in the December 2025 quarter at 2.75B. The Enterprise Value was at its lowest in in the March 2022 quarter at 0.

Mineralys Therapeutics, Inc. (MLYS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Mineralys Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Mineralys Therapeutics, Inc. (MLYS) Average Enterprise Value

How has MLYS Enterprise Value performed in the past?

The current Enterprise Value of Mineralys Therapeutics, Inc. (MLYS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Mineralys Therapeutics, Inc. (MLYS) Enterprise Value vs. Peers

How is MLYS’s Enterprise Value compared to its peers?

Mineralys Therapeutics, Inc.’s Enterprise Value is less than Cidara Therapeutics, Inc. (5.32B), less than Scholar Rock Holding Corporation (3.87B), less than IDEAYA Biosciences, Inc. (2.85B), less than Adaptive Biotechnologies Corporation (2.24B), less than Beam Therapeutics Inc. (2.56B), less than Catalyst Pharmaceuticals, Inc. (2.15B), greater than Zai Lab Limited (1.52B), less than Apellis Pharmaceuticals, Inc. (2.44B), less than Agios Pharmaceuticals, Inc. (1.58B), greater than Recursion Pharmaceuticals, Inc. (864.07M),

Build a custom stock screener for Mineralys Therapeutics, Inc. (MLYS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mineralys Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Mineralys Therapeutics, Inc. (MLYS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Mineralys Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.